Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 18/20 | 0.48 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12373851 | 0.89 | S1PR1 (0.50) | S1PR1S1PR3ALDH1A1CNR1CYP2C19 | |
| SCHEMBL12373858 | 0.87 | S1PR1 (0.48) | S1PR1S1PR3CNR1CYP2C19 | |
| SCHEMBL12373856 | 0.87 | S1PR1 (0.50) | S1PR1S1PR3ALDH1A1CNR1CYP2C19 | |
| SCHEMBL12373910 | 0.87 | S1PR1 (0.57) | S1PR1S1PR3ALDH1A1CNR1CYP2C19 | |
| SCHEMBL12373875 | 0.85 | S1PR1 (0.47) | S1PR1S1PR3SMN1; SMN2CNR1 | |
| SCHEMBL12373902 | 0.85 | S1PR1 (0.46) | S1PR1S1PR3ALDH1A1CNR1CYP2C19 | |
| SCHEMBL12373908 | 0.85 | S1PR1 (0.48) | S1PR1S1PR3ALDH1A1CNR1CYP2C19 | |
| SCHEMBL12249531 | 0.85 | S1PR1 (0.66) | S1PR1S1PR3CYP2C19 | |
| SCHEMBL12373819 | 0.83 | S1PR1 (0.49) | S1PR1S1PR3ALDH1A1SMN1; SMN2CNR1 | |
| SCHEMBL12373845 | 0.83 | S1PR1 (0.43) | S1PR1S1PR3ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7994204-B2 | Binding inhibitor of sphingosine-1-phosphate | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2011-08-09 | — | — | US | disclosed |
| US-7994204-B2 | Binding inhibitor of sphingosine-1-phosphate | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2011-08-09 | — | — | US | disclosed |
| US-20090182144-A1 | BINDING INHIBITOR OF SPHINGOSINE-1-PHOSPHATE | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2009-07-16 | — | — | US | disclosed |
| US-20090182144-A1 | BINDING INHIBITOR OF SPHINGOSINE-1-PHOSPHATE | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2009-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090182144-A1 | BINDING INHIBITOR OF SPHINGOSINE-1-PHOSPHATE | S1PR1, S1PR3, S1PR2 | S1PR1 1/4885S1PR3 2/4885ALDH1A1 2969/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.